

CD56 Antibody

Datasheet

For Research Use Only

Description	Catalog No.	Size
CD56 Concentrate	FP-A054-01	0.1 ml
CD56 Concentrate	FP-A054-05	1 ml
CD56 Predilute	FP-A054-70	7 ml

Description

Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.

Specifications

Clone	IHC056
Source	Mouse Monoclonal
Applications	IHC (P)
Formulation	Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide

IHC Procedure*

Positive Control Tissue	Neuroblastoma
Concetrated Dilution	1:50 – 1:200
Pretreatment	Perform heat-induced epitope retrieval (HIER) at pH 9 for 10 to 30 minutes
Incubation Time and Temp	10 to 30 minutes at room temperature
Detection	Refer to the detection system manual

*Result should confirmed by an established diagnostic procedure.

Result




Figure. CD56 on Adrenal Gland.

Storage and Handling

Must store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. To ensure proper stability and delivery of the antibody after each run, replace the cap and immediately place the bottle in a refrigerator in an upright position. Positive and negative controls should be simultaneously run with unknown specimens, as there are no conclusive characteristics to suggest instability of the antibody.

Precautions

For research use only. Do not use for diagnosis purpose.

References

1. **Gattenlöhner S**, et al. "Specific detection of CD56 (NCAM) isoforms for the identification of aggressive malignant neoplasms with progressive development." *Am J Pathol.* 2009 Apr;174(4):1160-71.
2. **Marafioti T**, et al. "Novel markers of normal and neoplastic human plasmacytoid dendritic cells." *Blood.* 2008 Apr 1;111(7):3778-92
3. **Chang CC**, et al. "Immunophenotypic profile of myeloid cells in granulocytic sarcoma by immunohistochemistry. Correlation with blast differentiation in bone marrow." *Br J Dermatol.* 1997 Dec;137(6):966-71.
4. **Savoia P**, et al. "CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease." *Br J Dermatol.* 1997 Dec;137(6):966-71.
5. **Natkunam Y**, et al. "Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases." *J Cutan Pathol.* 2000 Sep;27(8):392-9.
6. **Gerardy-Schahn R**, et al. "Hot spots of antigenicity in the neural cell adhesion molecule NCAM." *Int J Cancer Suppl.* 1994;8:38-42.
7. **Michalides R**, et al. "NCAM and lung cancer." *Int J Cancer Suppl.* 1994;8:34-7.
8. **Kibbelaar RE**, et al. "Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma." *Eur J Cancer.* 1991;27(4):431-5.
9. **Moolenaar CE**, et al. "Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212." *Cancer Res.* 1990 Feb 15;50(4):1102-6.
10. **Langdon SP**, et al. "Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines." *Cancer Res.* 1988 Nov 1;48(21):6161-5.
11. **Sumi M**, et al. "Natural killer cell lymphoma in the duodenum." *Leuk Lymphoma.* 2003 Jan;44(1):201-4.



12. Trejo O, et al. "Atypical cells in human cutaneous re-excision scars for melanoma express p75NGFR, C56/N-CAM and GAP-43: evidence of early Schwann cell differentiation." J Cutan Pathol. 2002 Aug;29(7):397-406.
13. Ely SA, et al. "Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation." Am J Pathol. 2002 Apr;160(4):1293-9.
14. Tao J, et al. "Aggressive Epstein-Barr virus-associated, CD8+, CD30+, CD56+, surface CD3-, natural killer (NK)-like cytotoxic T-cell lymphoma." Am J Surg Pathol. 2002 Jan;26(1):111-8.
15. Kaufmann O, et al. "Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections." Hum Pathol. 1997 Dec;28(12):1373-8.

Technical Support

Contact FemtoPath Technical Support at +886232338585 or email to femtopath@hongjing.com.tw for questions regarding this product.